Literature DB >> 2539179

Human hepatocellular cancers show decreased prostaglandin E1 binding capacity.

I Virgolini1, H Sinzinger, C Müller, M Hermann.   

Abstract

Specific binding of 3H-PGE1 to plasma membranes prepared from normal human hepatic tissue in the presence of Mg2+ reached saturation at concentrations greater than 50 nM, and could be displaced in the rank-order PGE1 greater than PGE2 greater than PGI2 greater than PGD2 greater than PGF2 alpha at 4 degrees C. Plasma membranes prepared from normal human hepatic tissue showed a high-affinity 3H-PGE1-binding capacity of 51.3 +/- 19.2 fmol mg-1 plasma membrane protein with an equilibrium dissociation constant of 3.8 +/- 1.9 nM, and a low-affinity 3H-PGE1-binding capacity of 104.2 +/- 17.3 fmol mg-1 protein with an equilibrium dissociation constant of 13.9 +/- 2.7 nM. Plasma membranes prepared from hepatocellular cancer tissue revealed a single class of binding sites with an apparent binding capacity of 38.4 +/- 17.3 fmol mg-1 plasma membrane protein (P less than 0.05) and an equilibrium dissociation constant of 12.1 +/- 2.8 nM. Competition studies on plasma membranes prepared from hepatocellular cancer tissue indicated no significant difference in the affinity of various prostaglandins to the receptor proteins as compared to normal hepatic tissue. It is assumed that the decreased 3H-PGE1-binding capacity found in human hepatocellular cancer tissue may reflect an alteration of the receptor protein content of the hepatocytes during carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539179      PMCID: PMC2247058          DOI: 10.1038/bjc.1989.81

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Hepatic alpha-adrenergic receptors. Identification and subcellular localization using [3H]dihydroergocryptine.

Authors:  W R Clarke; L R Jones; R J Lefkowitz
Journal:  J Biol Chem       Date:  1978-09-10       Impact factor: 5.157

2.  Effect of E-series prostaglandins on cyclic AMP-dependent and -independent hormone-stimulated glycogenolysis in hepatocytes.

Authors:  E P Brass; M J Garrity
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

3.  Glucagon and prostaglandin E1 stimulation of cyclic adenosine 3', 5'-monophosphate levels and adenylate cyclase activity in benign hyperplastic nodules and malignant hepatomas of ethionine-treated rats.

Authors:  R Chayoth; S M Epstein; J B Field
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

4.  Regulation of adenyl cyclase in hepatomas of different growth rates.

Authors:  D O Allen; J Munshower; H P Morris; G Weber
Journal:  Cancer Res       Date:  1971-05       Impact factor: 12.701

5.  Isolation of an organ specific protein antigen from cell-surface membrane of rat liver.

Authors:  D M Neville
Journal:  Biochim Biophys Acta       Date:  1968-04-09

6.  Identification of prostaglandin E metabolites from primary cultures of rat hepatocytes.

Authors:  T Okumura; R Nakayama; T Sago; K Saito
Journal:  Biochim Biophys Acta       Date:  1985-11-14

7.  Dissociation of E prostaglandin effects on liver glycogenolysis and cyclic AMP levels.

Authors:  F W Sweat; L Yamashita; W Jubiz
Journal:  Mol Cell Endocrinol       Date:  1983-10       Impact factor: 4.102

8.  Inhibitory effect of prostaglandins on the stimulation by glucagon and adrenaline of formation of cyclic AMP in rat hepatocytes.

Authors:  G O Brønstad; T Christoffersen
Journal:  Eur J Biochem       Date:  1981-07

9.  Effect of prostaglandins and hormones on cyclic AMP formation in rat hepatomas and liver tissue.

Authors:  G O Brønstad; T Christoffersen; E J Johansen; I Oye
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

10.  Decrease of prostaglandin I2 binding sites in thyroid cancer.

Authors:  I Virgolini; M Hermann; H Sinzinger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  3 in total

1.  Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression.

Authors:  Raymond L Konger; Glynis A Scott; Yvonne Landt; Jack H Ladenson; Alice P Pentland
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

Authors:  I Virgolini; C Müller; W Klepetko; P Angelberger; H Bergmann; J O'Grady; H Sinzinger
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

3.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.